5Tryptophan Depletion in Social Anxiety Disorder. Dr Sean HoodPresented at The European Certificate in Anxiety and Mood Disorders, Santa Margherita Ligure, 2000Explain ATDExplain disorder – specific provocations
6Study Protocol Overview Tryptophan Depletion: Serotonin & AnxietyStudy Protocol OverviewPatient fails to respond to standard open treatment (by CGI-I score): Routine outpatient careExclusion Criteria met: Routine outpatient careExclusion Criteria met: Routine outpatient careScreening DayStandard open treatment 3/12+ SSRIDay 1Day 2Post-Study Follow-upRecruitment
172004 Summer Conference of the British Association for Psychopharmacology. Harrogate, UK.
18Acute Tryptophan Depletion in 5 clinical anxiety disorders: PD, SAnD, PTSD, GAD & OCD NeurotalkJune 27th, 2010SingaporeProfessor Sean HoodConsultant PsychiatristUniversity of Western AustraliaPerth, Australia
26Serotonin – HPA Prolactin was also measured as it is known to be stress responsive(see Freeman et al., 2000).
27Serotonin – HPA 2 CO2 inhalation produced significant bradycardia compared with air inhalation, consistentwith previous findingsThis was not influenced bytryptophan depletion or related to plasma cortisollevels and is likely a parasympathetic responsediscrete from either sympathetic, HPA or arousalcentres (Kaye et al., 2006; Wetherell et al., 2006).
285HT & Hypertension & Stress (N) Volunteer Studies completed StudyATD35% CO2SSRICompletedPre-1: ATD Vols (Shufflebotham et al. 2006)Pre-2: CO2 Vols (Shufflebotham et al. 2009)Pre-3: ATD CO2 Vols (Hood et al. 2006)Pre-4: ATD CO2 SSRI Vols (Hince et al. 2010) (3 weeks)Study Pre-1: ATD Vols (Shufflebotham, Hood, Hendry, Hince, Morris, Nutt, Probert, & Potokar 2006)Firstly, we applied our ATD procedure to a group (n=11) of normal volunteers, who were matched to a convenience sample of 18 subjects with untreated Irritable Bowel Syndrome (IBS). We have reported elsewhere that IBS patients are a chronic disease group that exhibit depressive and anxiety symptoms in the subsyndromal range (Hood et al. 2008) and found that the IBS patients’ gastrointestinal and anxiety responses to changes in tryptophan load differ from that of normal volunteers. ATD in volunteers by itself exhibited no noticeable effect on psychological or cardiovascular outcomes.Study Pre-2: CO2 Vols (Shufflebotham, Wetherell, Hince, Hood, Lightman, Nutt, Probert, & Potokar 2009)Secondly, we isolated the 35% CO2 provocation variable in a similar group of normal volunteers (n=10) matched with untreated IBS patients (n=12). The 35% CO2 inhalation lead to an increase of anxiety, systolic blood pressure and cortisol levels in both groups, although the cardiovascular effect was enhanced in the IBS group.Study Pre-3: ATD CO2 Vols (Hood, Hince, Robinson, Cirillo, Christmas, & Kaye 2006)The logical progression was to combine the challenges of Study Pre-1 and Pre-2, thus in Study Pre-3 we examined both ATD and 35% CO2 provocation in normal volunteers. Independent effects of ATD (increasing cortisol, a trend for increase blood pressure) and 35% CO2 (increase cortisol, blood pressure & anxiety) were demonstrated but there was no ATD x 35% CO2 effect noted.Study Pre-4: ATD CO2 SSRI Vols (Hince, Menon, Shadianloo, & Hood 2010)Most recently, we have extended this series by adding a 3 week SSRI (escitalopram) versus placebo arm to the design of Study Pre-3, focussing on psychological and cardiovascular effects. Although adding an SSRI had no direct effect on anxiety measures an increase in diastolic blood pressure was seen, and the SSRI appeared to attenuate the 35% CO2-induced increase on anxiety.
295HT & Hypertension & Stress (N) Volunteer Studies over Past 5 Years Significant Outcome Measures for Normal VolunteersStudyPsychologicalCardiovascularEndocrinePre-1: ATD Vols (Shufflebotham, Hood, Hendry, Hince, Morris, Nutt, Probert, & Potokar 2006)Nil: ATD-Pre-2: CO2 Vols (Shufflebotham, Wetherell, Hince, Hood, Lightman, Nutt, Probert, & Potokar 2009)CO2 anxietyCO2 BPCO2 CortisolPre-3: ATD CO2 Vols (Hood, Hince, Robinson, Cirillo, Christmas, & Kaye 2006)Nil: ATD x CO2ATD BP (trend)ATD CortisolPre-4: ATD CO2 SSRI Vols (Hince, Menon, Shadianloo, & Hood 2010)Nil: 3 wk SSRINil: ATD x 3 wk SSRICO2 x 3 wk SSRI anxietyNil: 3 wk SSRINil: CO2 x 3 wk SSRIMessages:CO2 ... Is a powerful tool to produce psych + cvs + endocrine response in volsATD ... Increase cortisol and maybe mild pressor, but psych effect in normals unlikely
305HT & Hypertension & Stress (N) Volunteer Studies completed & proposed StudyATD35% CO2SSRICompletedPre-1: ATD Vols (Shufflebotham et al. 2006)Pre-2: CO2 Vols (Shufflebotham et al. 2009)Pre-3: ATD CO2 Vols (Hood et al. 2006)Pre-4: ATD CO2 SSRI Vols (Hince et al. 2010) (3 weeks)ProposedStudy 1: CO2 single dose SSRI (single dose)Study 2: ATD CO2 single dose SSRIStudy 1: To test the hypothesis that single dose SSRI treatment will increase the anxiety-inducing effects of 35% CO2 inhalation in healthy volunteers. Healthy volunteers (n=26) will be randomly allocated to either placebo or 10 mg escitalopram in a double blind manner. Three hours post ingestion of the medication (estimated to be with in the range of maximum plasma concentration for escitalopram (Sogaard B et al. 2005), participants will inhale a single breath of 35% CO2/air mixture. The psychological, cardiovascular and endocrine response to this stressor will be measured prior to and after the inhalation. We expect a greater stress response to the 35% CO2 challenge in the escitalopram group compared with the placebo group.Study 2: To test the hypothesis that single dose SSRI treatment increases the anxiety-inducing effects of 35% CO2 inhalation in healthy volunteers by increasing synaptic serotonin availability. Healthy volunteers (n=26) will be randomly allocated to either placebo or 10 mg escitalopram in a double blind manner. All participants will be tested twice separated by one week. On one test day, participants will be depleted of tryptophan and on the other, will not be depleted on the other. Order of depletion will be randomly determined for each participant and balanced across drug group, and both researcher and participant will be blind to group allocation. Three hours post ingestion of the depletion mixture, participants will inhale a single breath of 35% CO2/air. The psychological, cardiovascular and endocrine response to this stressor will be measured prior to and after the inhalation. We expect the following order of magnitude of stress response: escitalopram/not depleted = escitalopram/depleted ≥ placebo/depleted > placebo/not depletedStudy 3: To test the hypothesis that single dose SSRI treatment blocks the anxiety-inducing effects of 35% CO2 inhalation in normal volunteers due to participant expectation. Despite the double blind designs used in the studies proposed here and conducted previously, it is difficult to exclude expectation effects as 1) participants are aware that there is a 50% chance they will be given a medication that is expected to reduce their response to a stressor and 2) some participants may be away of symptoms produced by the medication and assume this means they are on active medication. To assess the role of expectation in the effect of escitalopram, healthy volunteers (n=x) will be randomized and assessed as described in Study 1. To experimentally manipulate expectation, half of each drug group will be told they have taken placebo, and half will be informed that they have taken escitalopram. If expectation is an important factor in SSRI effect of reducing 35% CO2 induced stress response, the following order of magnitude of effects will be observed: on placebo/told placebo=on escitalopram/told placebo > on placebo/told escitalopram=on escitalopram/told placebo consider within sub design? Would the models of SSRI action predict more anxiety with acute dose? We also need to know what acute dose does in patients I guess, although I know now practical. This requires more thought now, as participants might expect the SSRi to reduce anxiety because they think of it as a treatment for anxiety – will depend on what we tell them.
31Serotonin – Cardiovascular Cardiovascular response variables. Beat to beat blood pressure and heart rate will be recorded continuously across the challenge period using a non-invasive Task Force monitor.Autonomic response variables. Changes in cutaneous blood flow (an indication of flushing) and electrodermal skin response (an indication of changes in sweating) will be measured, as these autonomically mediated response to stress were important features of panic attacks in hypertensive individuals (9). Changes in cutaneous blood flow in the forehead and index finger will be measured using a laser Doppler flowmeter. This non-invasive technique involves shining a laser light onto the skin and applying the Doppler frequency shift principle to the reflected light in order to quantify the increase/decrease in blood flow. Changes in the electrodermal skin response will be measured using silver-silver chloride electrodes filled with conductive paste and attached to the second and third fingers.Psychological measures:Three subjective ratings of psychological variables will be used:Visual Analogue rating Scales (VAS), measured on 100mm line, anchored from 0: “not at all” to 100: “the most ... ever”. Subjects will be trained in the use of these scales as integer measures; these scales have been extensively validated (22;23).The Panic Symptom Inventory (PSI) lists 34 symptoms related to a panic attack with the option of rating 0 = not at all, 1 = slight, 2 = moderate, 3 = severe, 4 = very severe and has been used in studies of anxiety provocation (e.g. 54).The Spielberger State Anxiety Inventory (STAI).